Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

PURPOSE: Cabazitaxel has not been studied in patients with hepatic impairment (HI). This phase I study assessed cabazitaxel safety and pharmacokinetics in patients with HI. METHODS: Patients with advanced, non-hematologic cancer, and normal hepatic function (Cohort 1: C-1), or mild (C-2), moderate (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarantopoulos, John, Mita, Alain C., He, Aiwu, Wade, James L., Hsueh, Chung-Tsen, Morris, John C., Lockhart, A. Craig, Quinn, David I., Hwang, Jimmy, Mier, James, Zhang, Wenping, Wack, Claudine, Yin, Jian, Clot, Pierre-François, Rixe, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306058/
https://www.ncbi.nlm.nih.gov/pubmed/28058445
http://dx.doi.org/10.1007/s00280-016-3210-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306058/
https://www.ncbi.nlm.nih.gov/pubmed/28058445
http://dx.doi.org/10.1007/s00280-016-3210-8

Ejemplares similares